25-Hydroxyvitamin D and MS Activity During Therapy with Interferon Beta-1b
CMSC Conference, May 30, 2013 Florida
Alberto Ascherio, MD , Harvard University, Boston, MA
Kassandra Munger, ScD , Harvard University, Boston, MA
Claire Simon, ScD , Harvard University, Boston, MA
Ludwig Kappos, MD , University Hospital, Basel Neurology, Basel, Switzerland, Basel, Switzerland
Chris H Polman, MD , VU Medical Center, Amsterdam, Netherlands
Mark Freedman, MD , University of Ottawa, Ottawa, ON, Canada
Hans-Peter Hartung, MD , Heinrich-Heine University, Dusseldorf, Germany, Dusseldorf, Germany
David Miller, MBChB, MD, FRCP , UCL Institute of Neurology, London, United Kingdom
Xavier Montalban, MD , Hospital Universitari Vall d’Hebron, Barcelona, Spain
Gilles Edan, MD , CHU-Hôpital Pontchaillou, Rennes, France
Frederik Barkhof, MD, PhD , VU Medical Center, Amsterdam, Netherlands
Rupert Sandbrink, MD , Bayer Pharma AG, Berlin, Germany
Karl Kochert, MD , Bayer Pharma AG, Berllin, Germany
Christoph Pohl, MD , Department of Neurology, University Hospital of Bonn, Berlin, Germany
Background: Recently, various studies have been dissecting possible beneficial effects of 25-hydroxyvitamin D (25OHD) in reducing disease burden and MRI detectable disease activity in multiple sclerosis (MS).
Objectives: We studied the impact of 25(OH)D levels under interferon beta-1b (IFNB-1b) treatment on global gene expression levels with respect to the activity of MS.
Methods: BENEFIT studied IFNB-1b in patients with a clinically isolated syndrome (CIS). Within the first 2 years of the study, contrast-enhanced cerebral MRI scans and 25(OH)D were obtained at the CIS and after 6, 12, and 24 months. In addition, gene expression profiles in peripheral blood mononuclear cells (PBMC) were determined using Affymetrix HGU 133 plus 2 arrays at the CIS and after 2/3, 12 and 24 months. The association of ~19,000 genes with enhancing lesions, with 25(OH)D, and with IFNB-1b treatment was modeled with negative binomial and Gaussian generalized linear models. Gene set enrichment analysis (GSEA) was performed to test the association of previously described gene sets relevant for the function of IFNB-1b and 25(OH)D with the number of enhancing MRI lesions. For naïve, threshold based gene-function classification, the Database for Annotation, Visualization and Integrated Discovery (DAVID ) v6.7 was used.
Results: Higher 25(OH)D levels (p=0.0013) and IFNB-1b treatment (p<0.0001) were significantly associated with a lower number of enhancing lesions. 63 genes were significantly associated (p<0.05) with 25(OH)D levels; all but one of them were also associated with IFNB-1b treatment, which was significantly associated with 770 genes. GSEA showed that 25(OH)D gene sets reflecting the impact of vitamin D receptor binding on respective target genes as well as some IFNB-1b response gene sets were highly significantly associated with enhancing lesions. IFNB-1b and 25(OH)D regulated similar genes and first-line immune regulatory processes as shown by DAVID-based gene-function classification.
Conclusions: The results show a beneficial role of 25(OH)D on MS activity. On a molecular level in PBMCs, the mechanistic explanation for this effect is a systemic gene regulation by 25(OH)D which is part of a larger systemic gene response to IFNB-1b therapy. Genes associated with either of the 2 are mainly steering immunological processes that impact on the inflammatory activity of MS.
See also VitaminDWiki
- Overview MS and vitamin D
- Prevention with vitamin D in Multiple Sclerosis is logical – editorial April 2013
- Autoimmune disorder patients in Brazil helped by vitamin D – video and Facebook – Nov 2012
- Vitamin D can both prevent and treat Multiple Sclerosis – review Nov 2012
- Epigenetics, vitamin D, and Multiple Sclerosis
- Clinical trials for MS and Vitamin D INTERVENTION 33 as of Dec 2019
- All items in category MS and vitamin D
412 items - All items in category Genetics and vitamin D
343 items Items in both both of the categories Genetics and MS are listed here:
- People with Multiple Sclerosis have blunted responses to Vitamin D supplementation - Jan 2024
- Get Multiple Sclerosis while younger if have a poor CYP24A1 vitamin D gene – May 2023
- Vitamin D genes increase MS relapses in children by 2X – May 2019
- CYP2R1 gene problem increases Multiple Sclerosis risk by 1.4X – Dec 2018
- Multiple Sclerosis more likely if poor vitamin D genes - 22nd study – Aug 2017
- Mendelian proof that low vitamin D (due to 3 genes) increase risk of MS by 20 percent – Nov 2016
- Autoimmune risk gene ZMIZ1 is associated with both MS and Vitamin D – Jan 2017
- Multiple Sclerosis relapse in children is twice as likely having a Vitamin D Gene score of 6 – Oct 2016
- Multiple Sclerosis and obesity share some gene problems (as well as low vitamin D) – June 2016
- Genes make Multiple Sclerosis 2X more likely unless get more vitamin D - Aug 2015
- Multiple Sclerosis is connected to Vitamin D by gene to gene interactions – Aug 2014
- Multiple Sclerosis, gene expression, and vitamin D: Venn diagrams – Aug 2014
- Epigenetics of Multiple Sclerosis – March 2014
- Increased risk of multiple sclerosis risk in African Americans due to genes – June 2013
- 98 pcnt of genes that Vitamin D activates to reduce MS are also activated by Interferon -May 2013
- Transgeneration vitamin D deficiency related to MS was found in mice – Aug 2012
- Epigenetics, vitamin D, and Multiple Sclerosis
- Learning about MS and vitamin D in offspring from mice – Sept 2011
- Vitamin D targets 4 MS genes – May 2011
- Unable to find a gene linking vitamin D and MS – March 2011
- MS and vitamin D may be related by HLA gene – March 2010
- MS due to low level of vitamin D may be due to a specific gene – July 2010
Items in both both of the categories Vitamin D Receptor and MS are listed here:
- Multiple Sclerosis and Vitamin D Receptor Activators
- Multiple Sclerosis: is strongly related to poor Vitamin D receptors – umbrella review Oct 2024
- Poor Vitamin D Receptor increases the risk of Multiple Sclerosis in people of European descent – Feb 2024
- Multiple Sclerosis 2X-3X more likely if poor Vitamin D Receptor – Meta-analysis Feb 2020
- Risk of Multiple Sclerosis varies with the Vitamin D Receptor – meta-analysis Dec 2019
- Multiple Sclerosis and Vitamin D Receptor super enhancers – March 2019
- Vitamin D genes increase MS relapses in children by 2X – May 2019
- Immunological effects of vitamin D and their relations to autoimmunity – March 2019
- Inflammation and immune responses to Vitamin D (perhaps need to measure active vitamin D) – July 2017
- Multiple Sclerosis more likely if poor vitamin D genes - 22nd study – Aug 2017
- Multiple sclerosis (relapsing-remitting) increases activation of Vitamin D Receptor by 6.6 X – March 2017
- Multiple Sclerosis is more likely if poor Vitamin D Receptor (4X Mexico, 3X Iran)– Feb 2017
- Multiple Sclerosis much more likely if poor Vitamin D Receptor – several studies
- Multiple Sclerosis and the Vitamin D Receptor – meta-analysis July 2014
98 pcnt of genes that Vitamin D activates to reduce MS are also activated by Interferon -May 201310220 visitors, last modified 07 Dec, 2019, This page is in the following categories (# of items in each category) - All items in category Genetics and vitamin D